Targeted Oral Therapeutics

Advancing Precision Medicines for Immune-Mediated Diseases

Developing differentiated oral therapies designed to transform the treatment of immune-mediated and fibrotic diseases, beginning with inflammatory bowel disease.

Our Approach

Pipeline Overview

Clinical-Stage Company

Advancing lead program through Phase 2 clinical development.

Differentiated Oral Medicines

Designed to improve efficacy, safety and patient convenience with early clinical data showing encouraging response rates.

Immune & Fibrotic Diseases

Focused on areas of significant unmet medical need.

About Palisade Bio

Palisade Bio is a clinical-stage biopharmaceutical company developing differentiated oral therapeutics for immune-mediated and fibrotic diseases. Our lead program, PALI-2108, is advancing through Phase 2 clinical development for inflammatory bowel disease.

Learn More About Us

Our Approach

We seek to develop differentiated oral medicines by combining compelling biology, thoughtful drug design and disciplined clinical development.

Differentiated Science
Pursuing therapeutic approaches with the potential to meaningfully improve patient care.
Patient-Focused Development
Prioritizing efficacy, safety and convenience in the development of oral medicines.
Disciplined Execution
Advancing programs through focused, data-driven development.